Project Grant R01DC021452
- This federal Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD), under the Research Related to Deafness and Communication Disorders program (CFDA 93.173), provides $570,473.00 to Emory University for research on objective diagnostic measures to distinguish between adductor laryngeal dystonia (ADLD) and primary muscle tension dysphonia (PMTD). The key research objectives are to: 1) Investigate the underlying physiology of creak, a vocal...
- This Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD), under the federal grant program "Research Related to Deafness and Communication Disorders" (CFDA 93.173), provides $633,694 to North Carolina State University to develop a non-invasive treatment strategy using a vocal fold lamina propria extract (VFLPX) to address vocal fold scarring and laryngotracheal injuries. The key objectives are to: 1) conduct detailed investigations...
- This $600,000 project grant was awarded by the National Institute on Deafness and Other Communication Disorders (NIDCD) under the federal Research Related to Deafness and Communication Disorders program (CFDA 93.173). The grant, awarded to Northwestern University on September 18, 2025, will establish the validity of a vocal demand task outcome measure to assess vocal muscle strength capacity in older adults with presbyphonia (age-related voice changes). The project aims to determine if measuring...
- The federal Project Grant award of $340,417 from the National Institute on Deafness and Other Communication Disorders (NIDCD) under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) will fund research to evaluate the clinical efficacy of local translaryngeal vibration therapy (LTLV) as a concurrent treatment approach with flow phonation voice therapy for patients with muscle tension dysphonia, a common voice disorder. The research aims to determine the optimal...
- This $947,128 federal Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD), under the Research Related to Deafness and Communication Disorders program (CFDA 93.173), is funding research to optimize voice therapy for individuals with hyperfunctional voice disorders. The primary goal is to enhance long-term communication outcomes by evaluating a novel non-hierarchical voice therapy approach called Conversation Training Therapy (CTT), which focuses...
- This Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD), under the Research Related to Deafness and Communication Disorders program (CFDA 93.173), will support research to investigate vocal dysfunction and vagally mediated brainstem pathology in the prodromal stage of Parkinson's disease. The $126,442 award to the University of Wisconsin - Madison will fund a study using a rat model with a PINK1 gene knockout to evaluate differences in vocal,...
- This $631,703 federal Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD) under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) aims to investigate the use of muscle progenitor (stem) cells for treating vocal fold paralysis. The research project, conducted by The Washington University, will test the effectiveness of implanting these cells into the laryngeal muscles of canine models to improve nerve recovery...
- This federal Project Grant award of $405,748.00, awarded on June 9, 2025 by the National Institute on Deafness and Other Communication Disorders (NIDCD) under the Research Related to Deafness and Communication Disorders (CFDA 93.173) program, supports the development of noninvasive aerodynamic assessments for evaluating voice disorders in children aged 4-17. The project aims to improve the reliability of measuring aerodynamic parameters in the pediatric population and describe differences...
- This Project Grant award of $450,000 from the National Institute on Deafness and Other Communication Disorders (NIDCD), under the federal Research Related to Deafness and Communication Disorders program (CFDA 93.173), supports a research project to investigate the effects of omega-3 fatty acid supplementation on vocal performance and inflammation in professional female voice users. The project aims to determine the impact and feasibility of an omega-3 supplementation intervention on recovery...
- This $4.7 million project grant from the National Institutes of Health's National Institute of Neurological Disorders and Stroke will support the development of electrophysiological and ultrasound quantitative biomarkers for myofascial pain syndrome. The grant to Beth Israel Deaconess Medical Center will establish the use of electrical impedance myography, myofiber threshold tracking excitability testing, and ultrasound shear wave elastography to assess differences between patients with active...
FUNCTIONAL SYNERGISTIC PERILARYNGEAL MUSCLE NETWORK USING SYNCHRONIZED MULTI-SENSOR SURFACE ELECTROMYOGRAPHY TO IMPROVE DIAGNOSIS AND TREATMENT OF VOICE DISORDERS - PROJECT SUMMARY/ABSTRACT THERE IS A SIGNIFICANT GAP IN UNDERSTANDING AND QUANTIFYING VOCAL HYPERFUNCTION, A COMMON SYMPTOM IN PATIENTS WITH PHONOTRAUMATIC AND NONPHONOTRAUMATIC DYSPHONIA. VOCAL HYPERFUNCTION IS CHARACTERIZED BY EXCESSIVE PER- ILARYNGEAL MUSCLE ACTIVITY AND OFTEN LEADS TO MUSCLE PAIN, INCREASED VOCAL EFFORT AND STRAIN, AND VOCAL FATIGUE. CURRENT DIAGNOSTIC METHODS RELY HEAVILY ON SUBJECTIVE PATIENT REPORTS AND UNVALIDATED CLINICAL EVALUATIONS, MAK- ING IT CHALLENGING FOR CLINICIANS TO ACCURATELY DIAGNOSE AND TRACK TREATMENT OUTCOMES, WHICH ULTIMATELY IMPACTS THE QUALITY OF CARE PROVIDED TO THESE PATIENTS. THE PROPOSED RESEARCH AIMS TO ADDRESS THIS GAP BY DEVELOPING A NOVEL BIOMARKER OF VOCAL HYPERFUNCTION: FUNCTIONAL SYNERGISTIC PERILARYNGEAL MUSCLE NETWORK CONNECTIVITY USING SYNCHRONIZED MULTISENSOR SURFACE ELECTROMYOGRAPHY. THIS INNOVATIVE APPROACH WILL CREATE A NEW SPECTROTEMPO- RAL SYNERGISTIC SCAN TO QUANTIFY THE COMPLEX COORDINATION (AND DISCOORDINATION) OF PERILARYNGEAL MUSCLES DURING TYPICAL AND DYSPHONIC VOICING. THIS METHOD IS EXPECTED TO PROVIDE A MORE RELIABLE AND OBJECTIVE MEASURE OF VO- CAL HYPERFUNCTION. THE CENTRAL HYPOTHESIS IS THAT VOCAL HYPERFUNCTION IS CHARACTERIZED BY DISTURBANCES IN MUS- CLE COORDINATION DURING VOICING, WHICH CAN BE MEASURED USING THE FUNCTIONAL SYNERGISTIC PERILARYNGEAL MUSCLE NETWORK CONNECTIVITY SCANS. THIS HYPOTHESIS WILL BE TESTED IN THREE AIMS. AIM 1: DISTINGUISH PATTERNS OF PERI- LARYNGEAL MUSCLE DISCOORDINATION ACROSS DYSPHONIC CONDITIONS. AIM 2: QUANTIFY THE SYNERGISTIC PERILARYNGEAL NEUROMUSCULAR RESPONSE TO STANDARD TREATMENT. AIM 3: DETERMINE THE SYNERGISTIC PERILARYNGEAL NEUROMUSCULAR RESPONSE TO VOCAL DEMAND. THESE SPECIFIC AIMS WILL IMPROVE UNDERSTANDING OF THE VARIABLE PATHOPHYSIOLOGY OF VOCAL HYPERFUNCTION IN DIFFERENT TYPES OF DYSPHONIA. THE PROPOSED RESEARCH IS SIGNIFICANT BECAUSE IT WILL SHIFT OUR UNDERSTANDING OF VOICE DISORDERS BY PROVIDING AN OBJECTIVE BIOMARKER OF VOCAL HYPERFUNCTION PATHOPHYSIOLOGY. THIS APPROACH, CHARACTERIZED BY ITS OBJECTIVITY, RELIABILITY, REPEATABILITY, AND SPECIFICITY, IS CRUCIAL FOR ACCURATE DI- AGNOSIS. THIS WILL, IN TURN, ENHANCE THE DELIVERY OF EFFECTIVE CARE, PROMOTE EARLY DIAGNOSIS, REDUCE INSTANCES OF MISDIAGNOSIS, AND CONTRIBUTE TO THE ADVANCEMENT TOWARDS PRECISION MEDICINE. OBJECTIVE MEASUREMENT OF VO- CAL HYPERFUNCTION CAN ALSO HELP NAVIGATE TREATMENT PLANS BY TRACKING NEUROPHYSIOLOGICAL RESPONSES, ENABLING INFORMED THERAPY AND DOSING. ULTIMATELY, THE KNOWLEDGE GAINED FROM THIS RESEARCH HAS THE POTENTIAL TO INFORM FUTURE CLINICAL TRIALS ASSESSING THE PREDICTIVE ABILITY OF THIS BIOMARKER FOR TREATMENT RESPONSES FOR VOCAL HYPERFUNC- TION. THIS COULD LEAD TO A PARADIGM SHIFT IN THE MANAGEMENT OF VOCAL HYPERFUNCTION-RELATED DYSPHONIA, PAVING THE WAY FOR MORE TARGETED AND EFFECTIVE TREATMENTS
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $663.6k | 7/3/25 | ||
| Not listed | $0 | 4/8/25 | ||
| Not listed | $0 | 4/8/25 | ||
| Not listed | $687.9k | 7/5/24 | ||
| Not listed | $687.9k | 7/5/24 |